Study version

NeoNavia biopsy system has an innovative, patented pulse technology based on early research at Karolinska Institutet and is currently available in a CE-marked study version. (CE-certificate granted in July 2016)

The study version has two innovations;

1. The pulse technology for controlled needle insertion and precise placement in a suspicious lesion
2. A patented open-tip front loaded biopsy needle with the same diameter as a core-needle, i.e. 14 G.

The NeoNavia open tip biopsy needle is developed in close collaboration with physicians with the aim to facilitate tissue sampling of small lesions and other hard to sample cases.

For example:

• Tumors smaller than 10 mm in diameter
• Tumors near the chest wall
• Tumors near the skin
• Tumor adjacent to silicon implants
• Calcified Lesions
• Axillary lymph nodes

NeoNavia study version with the pulse technology and open-tip needle design has been validated in breast and axilla biopsy procedures on more than 500 patients at 15 leading European cancer clinics.

Read about our publications and ongoing clinical studies.

Pre-Clinical data on NeoNavia study version
The open tip needle in the NeoNavia mpulse biopsy system delivered at least 3x the sample weight compared to the market leader incorporating the same needle diameter.¹

Bench-testing was performed in three different tissue models (turkey breast Pancreas and thymus) representing a wide variety of tissue structures. 

Results from the NeoNavia system were compared with the market leader incorporating the same needle diameter. In all cases the NeoNavia Biopsy System delivered at least 3x the sample weight compared to the market leader incorporating the same needle diameter.¹